Who is sponsoring NCT06749028?

NCT06749028 is sponsored by Fundación del Caribe para la Investigación Biomédica.

What drugs are being tested in NCT06749028?

Interventions in NCT06749028: Intervention Arm: Omega-3 + Phospholipids., Comparator Arm: Omega-3 alone..

What condition does NCT06749028 study?

NCT06749028 studies Hypertriglyceridemia.

Is NCT06749028 still recruiting?

NCT06749028 is currently active, enrolled. Last updated 17 July 2025.

Last reviewed 2025-07-17 · How we verify

NCT06749028: OMEGA-PHYT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy of Phospholipid-Bound Omega-3 Versus Omega-3 Alone in Patients With Hypertriglyceridemia: A Randomized Clinical Trial

Active, enrolled NA Last updated 17 July 2025

What this trial tests

NA trial testing Intervention Arm: Omega-3 + Phospholipids. in Hypertriglyceridemia in 44 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 December 2024

Primary endpoint
20 May 2025

31 August 2025

Quick facts

Lead sponsor	Fundación del Caribe para la Investigación Biomédica
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	44
Start date	17 December 2024
Primary completion	20 May 2025
Estimated completion	31 August 2025
Sites	1 location across Colombia

Drugs / interventions tested

Intervention Arm: Omega-3 + Phospholipids.
Comparator Arm: Omega-3 alone.

Conditions studied

Hypertriglyceridemia — all drugs for Hypertriglyceridemia →

Sponsor

Fundación del Caribe para la Investigación Biomédica

Who can join

Adults 18 to 65, any sex, with Hypertriglyceridemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypertriglyceridemia is a significant risk factor for cardiovascular diseases. Omega-3 fatty acids have been shown to reduce triglyceride levels, and their combination with phospholipids could offer additional benefits in improving lipid profiles and inflammatory markers. This study aims to evaluate the efficacy of combining omega-3 with phospholipids compared to omega-3 alone in patients with hypertriglyceridemia. The objective of the clinical trial is to provide robust evidence on the benefits of this combination in improving lipid profiles and reducing inflammation, which could have a significant impact on clinical practices and future dietary recommendations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of phospholipid-bound omega-3 versus standard omega-3 in patients with hypertriglyceridemia: a randomized clinical trial.
Urina-Triana M, David-Pardo DG, Urina-Triana M, Valencia J, et al · · 2026 · PMID 41514392 · DOI 10.1186/s12906-026-05245-1

Verify or expand the search:

Other recruiting trials for Hypertriglyceridemia

Currently open trials in the same condition.

NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07004777 — Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition · NA · recruiting
NCT07140809 — a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia · Phase 1, PHASE2 · recruiting
NCT06494488 — Differential Thrombogenesis by EPA and DHA Mediated by HDL · EARLY_PHASE1 · recruiting
NCT06783881 — Single-ascending Dose Study of Kylo-12 in Healthy Subjects · Phase 1 · active not recruiting

Other Fundación del Caribe para la Investigación Biomédica trials

Trials by the same sponsor.

NCT03643536 — 12-week Exercise-based Program in Myocardial Revascularization Subjects · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06749028 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación del Caribe para la Investigación Biomédica
Last refreshed: 17 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing